Ian Lyall

London

Managing Editor at Proactive Investors UK

Tracking tomorrow’s blue-chips

Featured in: Favicon

proactiveinvestors.co.uk

linkedin.com Favicon

msn.com

dailymail.co.uk Favicon

thisismoney.co.uk Favicon

proactiveinvestors.com Favicon

expressdigest.com Favicon

proactiveinvestors.com.au Favicon

newsamed.com Favicon

amedpost.com + 5 more

Articles

SMALL CAP IDEA: Poolbeg Pharma raises £4.1m to finance cancer drugs

5 days ago | thisismoney.co.uk | Ian Lyall

Raising fresh capital is a familiar rhythm for early-stage biotech companies. For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them. Expert opinion is broadly optimistic on this point - bolstered by a major tick in the box from the US regulator.
Aura Energy signs uranium collab in Sweden

5 days ago | proactiveinvestors.com.au | Jamie Ashcroft |Ian Lyall

About Jamie Ashcroft Jamie Ashcroft, the News Editor for Proactive UK, has developed an impressive career in financial journalism, focusing on the small-cap sector for over fourteen years. Before joining the Proactive team, he was a stockbroker during the global financial crisis, a role that complemented his educational background - a first-class degree in Business and Economics and qualifications in software design and development.
Why gold mining shares are too cheap, according to JP Morgan analysts

1 week ago | msn.com | Ian Lyall

Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
Why gold mining shares are too cheap, according to JP Morgan analysts

1 week ago | thisismoney.co.uk | Ian Lyall

After a strong run for precious metals, gold mining shares still look undervalued. That’s the view from JP Morgan’s latest note on listed producers, which argues there’s room for substantial upside, especially if its bullish forecast for the precious metal proves right. Its commodities team is pencilling in a price of $4,100 an ounce for 2026. That’s well above current spot levels of $3,320 and would mark a new all-time high.
Rio Tinto's lithium strategy: Analyst cautious despite expansion

1 week ago | proactiveinvestors.com.au | Ian Lyall

About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually.
Genedrive wins EU approval for genetic test used in stroke care

1 week ago | proactiveinvestors.com | Ian Lyall

HealthPharma & Biotech This record is published on behalf of genedrive PLC, a paid client of ProactiveAbout this content Disclaimer No investment advice About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive.
hVIVO flags contract setback and record order book

1 week ago | proactiveinvestors.com | Ian Lyall

hVIVO PLC (AIM:HVO) has reported the cancellation of one trial and the postponement of another, but said its pipeline of new business has reached record levels, with several large contracts in late-stage negotiations. The London-listed clinical research group, which specialises in human challenge trials (HCTs), said the changes were driven by wider uncertainty in the pharmaceutical sector and weak biotech funding, particularly in the United States.
Explained: Nvidia’s results and what they mean for UK investors

1 week ago | proactiveinvestors.com.au | Ian Lyall

Nvidia Corp (NASDAQ:NVDA, ETR:NVD) latest quarterly earnings once again cement its position at the forefront of the artificial intelligence boom, delivering headline-grabbing growth that pushed its shares up 5% in extended trading. For UK investors, many of whom hold Nvidia indirectly through global technology funds, ETFs and directly through ISAs, this performance matters. Revenue came in at $44.06 billion, well ahead of expectations and 69% higher than a year ago.
Apple sheds nearly $70bn as Jony Ive and Sam Altman hint at new AI device after $6.4bn acquisition

2 weeks ago | proactiveinvestors.com.au | Ian Lyall

Nearly $70 billion was wiped from Apple Inc's (NASDAQ:AAPL, ETR:APC) market value amid mounting speculation that OpenAI and former Apple designer Jony Ive are preparing to unveil a next-generation artificial intelligence-supported device, following confirmation of OpenAI’s largest acquisition to date. The ChatGPT maker is paying $6.4 billion to acquire io, a little-known hardware start-up launched a year ago by Ive and a group of former Apple colleagues.
Wise finds its footing in crowded markets as investor support builds

2 weeks ago | proactiveinvestors.com.au | Ian Lyall

Wise PLC (LSE:WISE), the money transfer and payments group, heads into its full-year results next month with growing momentum and a supportive backdrop. Shares in the company have gained more than 20% this year, and analysts at JP Morgan see further upside, lifting their price target to £13.75 from £12.42 and maintaining an 'overweight' rating.